Nonclinical precedent Request an invite
Species
Mouse only (CD18HYP/CD18KO disease models, recipient mice, NSG mice); no large-animal tox
“The applicant also used surrogate Lin- HSPCs transduced with the Chim-CD18-WPRE LV transplanted into recipient mice for their definitive in vivo toxicology and BD studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Why that species
CD18-deficient mice mimic LAD-I phenotype (impaired neutrophil migration); patient CD34+ cells unavailable
“CD18HYP and CD18KO mice have deficient CD18 expression and impaired neutrophil migration and inflammatory responses similar to LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 3Source ↗
Surrogate molecule
Yes: murine Lin- HSPCs transduced with clinical vector; healthy-donor human CD34+ cells in NSG mice
“The final clinical product and source material was not used in the nonclinical studies summarized in this memo due to feasibility issues obtaining sufficient CD34+ HSCs from LAD-I patients.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: general tox
Mouse only (recipient mice transplanted with transduced murine Lin- HSPCs)
“The applicant also used surrogate Lin- HSPCs transduced with the Chim-CD18-WPRE LV transplanted into recipient mice for their definitive in vivo toxicology and BD studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗
Species: DART
Not conducted (product type; reproductive-tissue biodistribution near background)
“Studies were not conducted to evaluate this developmental and reproductive toxicity based on the product type and due to the lack of concerning findings in reproductive tissues in Study #7 (study report no. NSR-7).”
✓ VerifiedFDA pharmacology/toxicology review, p. 25Source ↗
Species: carcinogenicity
Not conducted (traditional studies not suitable for this product type)
“Traditional carcinogenicity studies were not conducted since they are not suitable for assessment of this drug product type.”
✓ VerifiedFDA pharmacology/toxicology review, p. 26Source ↗
Surrogate used in
Yes: CD18HYP/CD18KO mouse Lin- HSPCs transduced with the clinical vector for in vivo pharmacology
“The applicant also used surrogate Lin- HSPCs from CD18HYP and CD18KO mice transduced with the clinical vector to demonstrate donor cell engraftment and improved neutrophil extravasation to tissue-specific sites of inflammation for the in vivo pharmacology studies.”
✓ VerifiedFDA pharmacology/toxicology review, p. 8Source ↗

Same question, other gene therapies

Adstiladrin

nadofaragene firadenovec · IFN-alpha2b (adenovirus, intravesical)
Cynomolgus monkey for rAd-IFN/Syn3 GLP tox; rat and monkey for excipient Syn3

Beqvez

fidanacogene elaparvovec · Factor IX
Cynomolgus monkey and mouse (tox); hemophilia B dog and mouse (pharmacology); rabbit (shedding)

Casgevy

exagamglogene autotemcel · BCL11A enhancer (CRISPR-Cas9, ex vivo HSC)
Mouse only (irradiated NSG immunodeficient xenotransplant mice)

Elevidys

delandistrogene moxeparvovec · Micro-dystrophin
Mouse only (wild-type C57BL/6J and mdx disease model); NHP only in non-GLP supporting studies

Fayuvi

rebisufligene etisparvovec · SGSH (AAV9)
Wild-type C57BL/6 mice only (6-month and 3-month GLP studies)

Genglycos

pariglasgene brecaparvovec · G6PC (AAV8)
Mouse (adult and juvenile C57BL/6N) and juvenile cynomolgus monkey; GLP single-dose studies

Glybera

alipogene tiparvovec · LPL (AAV1)
Wild-type mouse only for GLP tox; PD in LPL-/- mice and LPL-deficient cats; biodistribution in cats, mice, rabbits

Hemgenix

etranacogene dezaparvovec · Factor IX
Mouse and cynomolgus monkey

Imlygic

talimogene laherparepvec · GM-CSF (oncolytic HSV-1)
Mouse (BALB/c) for GLP tox; single-dose studies also in rats and dogs; no permissive/relevant species for human GM-CSF

Itvisma

onasemnogene abeparvovec (intrathecal) · SMN1 (AAV9, intrathecal)
Cynomolgus monkey (pivotal IT tox); FVB mice for ICV safety and fertility/EFD; SMA piglet and SMN-delta7 mouse pharmacology

Kebilidi

eladocagene exuparvovec · AADC
Rat (pivotal GLP); cynomolgus monkey for biodistribution/excipient studies

Lenmeldy

atidarsagene autotemcel · ARSA (LVV, ex vivo HSC)
Mouse (As2-/- MLD model, murine ARSA-LV HSPCs) for pivotal GLP; immunodeficient mice for human-cell biodistribution

Luxturna

voretigene neparvovec · RPE65
Dog (normal-sighted and RPE65-mutant Briard) and non-human primate

Lyfgenia

lovotibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Mouse only (beta-thalassemic and wild-type C57BL/6 transplant models; immunodeficient mice for human cells)

Otarmeni

lunsotogene parvec · OTOF (AAV, intracochlear)
Mouse (Otof-Q828X hom disease model) and cynomolgus monkey

Papzimeos

zopapogene imadenovec · HPV6/11 antigens (gorilla adenovirus)
Mouse only (wild-type C57BL/6); no NHP studies

Roctavian

valoctocogene roxaparvovec · Factor VIII
Mouse (CD1, Rag2-/-, hemophilia A models) and cynomolgus/rhesus monkey; all males

Skysona

elivaldogene autotemcel · ABCD1 (LVV, ex vivo HSC)
Mouse only: myeloablated immunodeficient NSG/NSGS mice given human CD34+ HSCs

Strimvelis

autologous CD34+ cells transduced with ADA (no INN) · ADA (gamma-retroviral, ex vivo HSC)
NSG immunodeficient mouse only (xenograft of transduced human CD34+ cells)

Tudriqev

vusolimogene oderparepvec · GALV-GP + GM-CSF (oncolytic HSV-1)
Tumor-bearing immunocompetent mice (TUDRIQEV, mRP1) and healthy rats (murine surrogate mRP1)

Vyjuvek

beremagene geperpavec · COL7A1 (HSV-1, topical)
Mouse only (BALB/c) for GLP tox; single species

Waskyra

etuvetidigene autotemcel · WAS (LVV, ex vivo HSC)
Mouse only: WAS knockout (C57BL/6 and SV129) mice with murine surrogate cells; Rag2-/-IL2rg-/- mice for human-cell fate

Zevaskyn

prademagene zamikeracel · COL7A1 (RV-modified keratinocyte sheets)
Mouse only (immunodeficient mice with implanted human keratinocyte products); no relevant large-animal species

Zolgensma

onasemnogene abeparvovec · SMN1
Mouse only for pivotal GLP tox (neonatal FVB); NHP only in non-GLP studies (later 6-month juvenile NHP study in label)

Zynteglo

betibeglogene autotemcel · HBB T87Q (LVV, ex vivo HSC)
Mouse only (beta-thalassaemic Hbbth1/th1 and wild-type C57BL/6; immunodeficient NSG for human HSC); murine surrogate product

Summary across all 26 gene therapies →